Results 21 to 30 of about 5,807 (256)

Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers

Frontiers in Immunology, 2023
T cell engagers, a category of T cell-retargeting immunotherapy, are rapidly transforming clinical cancer care. However, the lack of tumor-specific targets poses a significant roadblock for broad adaptation of this therapeutic modality in many ...
Even Walseng, Bo Wang, Chunning Yang, Pooja Patel, Chihao Zhao, Hanzhi Zhang, Peng Zhao, Yariv Mazor   +7 more
doaj   +1 more source

Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins

Frontiers in Immunology, 2022
Despite the availability of an effective prophylactic vaccine, 820,000 people die annually of hepatitis B virus (HBV)-related liver disease according to WHO.
Bilge Debelec-Butuner, Bilge Debelec-Butuner, Oliver Quitt, Sophia Schreiber, Frank Momburg, Karin Wisskirchen, Karin Wisskirchen, Ulrike Protzer, Ulrike Protzer   +8 more
doaj   +1 more source

CD3‐T‐cell‐engager (TCE) therapies to overcome solid tumors: Beyond BiTEs

MedComm – Biomaterials and Applications, 2022
CD3‐T‐cell‐engager (TCE) therapies, such as bispecific T‐cell engagers (BiTEs), have achieved extraordinary success in treating hematological malignancies and have shown therapeutic effects comparable with those of chimeric antigen receptor (CAR)‐T ...
Jiali Zhang, Qianqian Guo, Quan Wang, Yourong Duan   +3 more
doaj   +1 more source

Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity

Communications Biology, 2021
Mandrup et al. describe a panel of recombinant albumin fusions, engineered with different affinities to the human neonatal Fc receptor to program the half-life extension of a bispecific (EGFR/CD3) T-cell engager.
Ole A. Mandrup, Sui Ching Ong, Simon Lykkemark, Anders Dinesen, Imke Rudnik-Jansen, Niels Frederik Dagnæs-Hansen, Jan Terje Andersen, Luis Alvarez-Vallina, Kenneth A. Howard   +8 more
doaj   +1 more source

T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC

Molecular Therapy: Oncolytics, 2017
The outcome for advanced stage hepatocellular carcinoma (HCC) remains poor, highlighting the need for novel therapies. Genetically modified mesenchymal stem cells (MSCs) are actively being explored as cancer therapeutics due to their inherent ability to ...
Arpad Szoor, Abishek Vaidya, Mireya Paulina Velasquez, Zhuyong Mei, Daniel L. Galvan, David Torres, Adrian Gee, Andras Heczey, Stephen Gottschalk   +8 more
doaj   +1 more source

Progress of research on PD-1/PD-L1 in leukemia

Frontiers in Immunology, 2023
Leukemia cells prevent immune system from clearing tumor cells by inducing the immunosuppression of the bone marrow (BM) microenvironment. In recent years, further understanding of the BM microenvironment and immune landscape of leukemia has resulted in ...
Huizhen Cao, Tianyu Wu, Xue Zhou, Shuyang Xie, Hongfang Sun, Yunxiao Sun, Youjie Li   +6 more
doaj   +1 more source

Evaluation of an anti-CD3 VHH and construction of an anti-CD3/anti-EGFR bispecific tandem VHH as a cancer cell targeting drug construct

Biochemistry and Biophysics Reports
Recently, the development of T-cell engager cancer therapeutics, consisting of anticancer and anti-T-cell antibody parts to engage the T-cell to the cancer site, has gained interest.
Takuya Asanuma, Peiwei Ding, Yuki Kato, Takeshi Nakanishi, Ryutaro Asano, Koki Makabe   +5 more
doaj   +1 more source

Engaging T cells for cleanup

Frontiers in Immunology
T-cell engagers represent a transformative approach to cancer immunotherapy leveraging bispecific and multispecific antibody constructs to redirect T-cell cytotoxicity toward malignant cells. These molecules bridge T cells and tumor cells by simultaneously binding CD3 on T cells and tumor-associated antigens on cancer cells, thereby enabling precise ...
Roman V. Mungalov, Roman V. Mungalov, Roman V. Mungalov, Natalia V. Mushenkova, Natalia V. Mushenkova, Dmitriy M. Chudakov, Dmitriy M. Chudakov, Dmitriy M. Chudakov, Dmitriy M. Chudakov, Dmitriy M. Chudakov, Maria A. Turchaninova, Maria A. Turchaninova   +11 more
openaire   +3 more sources

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma

OncoImmunology, 2022
B cell lymphoma therapy has been transformed by CD19-targeting cellular therapeutics that induce high clinical response rates and impressive remissions in relapsed and refractory patients.
Lihe Su, Lan Wu, Roy R. Lobb, Paul D. Rennert, Christine Ambrose   +4 more
doaj   +1 more source

A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2⁺ Solid Cancer

Cells, 2023
The efficacy of CD19-specific CAR T cells in the treatment of leukemia/lymphoma relies, at least in part, on the unique properties of the particular CAR and the presence of healthy B cells that enhance the target cell lysis and cytokine secretion through
Andreas A. Hombach, Christine Ambrose, Roy Lobb, Paul Rennert, Hinrich Abken   +4 more
doaj   +1 more source